CA-TIGO
21.2.2024 15:01:30 CET | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the launch of the GO EV Charger for the Italian market. A smart residential electric vehicle (EV) charging station, GO EV Charger offers solar installers a way to add e-mobility that seamlessly integrates with the Tigo EI (Energy Intelligence) Residential Solar Solution, which includes inverter, battery system, TS4 MLPE devices, and everything else required for fast, flexible, and dependable solar installations. The Tigo EI Residential Solar Solution will be on display from February 28th to March 1st at KEY - The Energy Transition Expo in Rimini, Italy.
Previously released for the German market, the GO EV Charger features seamless integration with the Tigo EI Residential solar-plus-storage solution. The GO EV Charger is available in single- or three-phase variants, up to 22 kW, and delivers high flexibility with multiple charging modes, current limits, and scheduling options. In addition to integrated RFID for authorized-user identification, end-users can manage the GO EV Charger remotely through the Tigo Energy Intelligence (EI) app. The Tigo Energy Intelligence platform also provides powerful commissioning, monitoring, and fleet management functions for installers. The Tigo GO EV Charger features a protective enclosure for indoor or outdoor installation and a 60-month warranty.
“We take pride in providing our customers with a system that not only delivers high performance, ease of use, and reliability but empowers us on the installer side to provide outstanding support remotely,” said Quinto Ferri, Owner of Ferri Quinto & C. s.n.c. “We rely on the Tigo EI Residential solution because it is designed to enable faster installation and commissioning, thus allowing our customers to benefit from solar energy sooner. We also understand that every customer's energy requirements are unique, so the flexibility offered by Tigo's solar-plus-storage solution allows us to provide bespoke solutions that cater to each individual's needs and help them achieve their specific energy goals.”
“Solar installers like Quinto lead the way in sustainable home energy in Italy, and with a record of multiple Tigo EI Residential systems already deployed, Ferri Quinto & C. s.n.c. has repeatedly demonstrated their ability to design winning unique solutions that meet customer needs,” said Mirko Bindi, Senior VP Sales EMEA & MD Europe at Tigo Energy. “Exciting times ahead as we unveil a captivating array of innovative solutions, further enriching our products and services our installations partners can offer their customers. As the stack of Tigo EI Residential products expands with options like EV charging, homeowners benefit from a home energy system that optimizes production and consumption, enabling the best possible return on investment.”
In the European market, the Tigo EI Residential Solar Solution now includes the Tigo GO EV Charger as well as Tigo TS4 Flex MLPE products, single-phase and three-phase Tigo inverters, modular DC-coupled Tigo energy storage components, and the Tigo EI Link device. The Tigo TS4 platform is a fundamental building block for solar systems of all sizes and significantly increases energy production by mitigating the impact of shading and module mismatch, providing first-responder safety with rapid shutdown, and enabling system performance insights through module-level monitoring. With module-level monitoring, Tigo EI software processes energy data from the EI Residential System, allowing system owners to manage and monitor energy and installers to monitor and manage their fleets of customer systems efficiently. Since 2007, Tigo has deployed 3.5 GW of Tigo MLPE devices across more than 100 countries on all seven continents, of which Tigo Energy Intelligence monitors more than 1 GWh of daily solar production.
Learn more about Tigo solutions at KEY – The Energy Transition Expo (Quartiere Fieristico di Rimini, Italy, Pav. D1, Booth 001) from February 28th to March 1st. Please use this link to schedule a meeting with a Tigo representative or view the list of Tigo partners exhibiting at the event.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221652197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom